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According to the World Health Organization (WHO), 
South Africa (SA) was one of five countries with the 
highest TB incidence in 2011, estimated at 500 000 
new TB cases and approximately 25 000 deaths.[1]
In 2009 the South African National Tuberculosis 
Programme (NTP) released new national tuberculosis management 
guidelines for healthcare personnel and managers.[2] The guidelines 
include treatment strategies suggested by the WHO and recommend 
that all patients receive directly observed therapy (DOT) for the 
entire treatment course. However, despite NTP efforts to improve 
access to treatment and treatment adherence among TB patients, the 
proportion with successful treatment outcomes remains low (79% 
v. target of 86% cured or completed treatment) and mortality rates 
remain high (49/100 000).[1] Patients in whom treatment fails or who 
do not complete treatment are at risk for acquisition of drug-resistant 
TB, additional morbidity, and mortality.
A patient’s ability to adhere to TB treatment is a complex, dynamic 
phenomenon with a wide range of factors impacting on treatment-
taking behaviour. Non-adherence to assigned treatment has been 
cited as the major barrier to TB control worldwide.[3-8] Although 
DOT has been well documented to improve patient adherence to 
TB treatment and optimise treatment outcomes,[4-6] studies have 
reported that DOT coverage remains low in many parts of the world, 
including SA.[3-6] A study conducted in the North West Province of 
SA found that the proportion of TB patients receiving DOT was as 
low as 56.8%, with coverage lowest among TB retreatment patients,[5] 
while another in KwaZulu-Natal reported that only 43 of 70 priority 
facilities (61%) had a DOT programme.[6]
Furthermore, although countries have implemented the WHO-
recommended directly observed, short-course (DOTS) strategy[7] 
that includes DOT along with four other components, individual 
healthcare workers (HCWs) may not be aware of or fully informed 
about the strategy, may not be willing to implement it, or may not 
have the resources to implement it. Studies have reported that not all 
HCWs have been exposed to the national TB treatment guidelines, 
and many are not prescribing recommended regimens.[8-10] A 2012 
systematic review that included 31 studies from 14 countries cited 
wide variation in HCW knowledge of treatment regimens (8 - 100%) 
and treatment duration (5 - 99%).[11] According to another recent 
review, inappropriate treatment regimens were often prescribed 
to patients (in 67% of 37 studies included in the review), with the 
proportion of patients on inappropriate treatment regimens ranging 
between 0.4% and 100%.[12]
In SA, while several studies evaluating DOT have been 
conducted,[5-6] the effect on treatment outcomes of failing to adhere 
to guidelines for standard treatment regimens and DOT has not been 
investigated previously. Knowledge of the impact of non-adherence 
to standard regimens and DOT on treatment outcomes will allow 
programmes and clinicians to recognise practices essential to treat 
and manage patients with TB effectively.
We aimed to describe treatment management practices in three 
SA provinces, including assignment of treatment regimen and DOT 
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Background. Standardised tuberculosis (TB) treatment through directly observed therapy (DOT) is available in South Africa, but the level 
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Conclusion. Patients who received incomplete DOT or had a history of defaulting from TB treatment had an increased risk of poor 
outcomes.
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coverage for TB patients; evaluate treatment 
regimen practices and DOT coverage in the 
context of national TB treatment guidelines; 
and assess the impact of failing to adhere to 
standard treatment regimens and DOT on 
TB treatment outcomes.
Methods
We conducted a secondary analysis of 
data collected as part of a parent project 
aimed at evaluating the TB surveillance and 
electronic tuberculosis registry (ETR) in 
SA.[13] The parent project included 1 339 
patients diagnosed with TB in the first 
quarter of 2009 in Gauteng, KwaZulu-Natal 
and Mpumalanga provinces. Information 
on key TB variables was abstracted onto 
standardised forms from multiple data 
sources, including the patient treatment 
card, the paper TB register at the health 
facility, and the ETR[14] at the sub-district 
(initial), district, provincial and national 
levels. Owing to missing information in 
the ETR at these district, provincial and 
national levels, the current analysis was 
restricted to the three initial data sources: 
patient treatment card, TB register and 
initial ETR. We used the following decision 
rules to resolve discrepant information 
from the multiple data sources: (i) if there 
was information in all 3 data sources, we 
accepted the variable value reflected in 2 of 3 
sources; (ii) if 3 or 2 data sources had a value 
available but all had different values, the 
value in the TB register was used; and (iii) if 
only 1 data source had information available, 
we took the value from this source.
Our analysis included all TB patients in 
the parent project for whom information 
was available on TB treatment regimen, 
DOT coverage, and treatment outcome in at 
least one data source. All cases with missing 
information on TB treatment regimen, DOT 
coverage or treatment outcome and those who 
moved or transferred out during the current 
treatment episode were excluded. Treatment 
regimens were categorised as appropriate or 
inappropriate based on national guidelines.[2] 
The guidelines include WHO-recommended 
treatment strategies for new patients (regimen 
1), retreatment patients (regimen 2) and 
children (regimen 3).[2] Adults and children 
aged 8 years and older with no history of a 
previous TB episode who were prescribed 
standard therapy (regimen 1) were considered 
to be on appropriate therapy; all other 
regimens for these patients were classified 
as inappropriate. Regimen 2 was considered 
appropriate for retreatment patients, and 
regimen 3 was considered to be appropriate 
for children younger than 8 years of age; 
other regimens prescribed for these patient 
groups were considered inappropriate. DOT 
adherence was categorised as full for those 
who received DOT during the entire course of 
TB treatment (100% of doses through DOT), 
partial for patients receiving DOT during 
either the intensive or the continuation 
phase, and no DOT for patients who were 
not provided any DOT during treatment. 
Death, treatment failure and default were 
considered poor TB treatment outcomes; cure 
and treatment completion were considered 
successful outcomes.
Risk ratios (RRs) and 95% confidence 
intervals (CIs) were used to measure the effect 
of adherence to standard treatment regimens 
and DOT on treatment outcomes. Univariate 
associations were further examined to 
identify potential confounders and effect 
modifiers. A multivariate log-binomial 
regression model was developed to identify 
independent predictors of poor treatment 
outcome among TB patients. Variables with 
an established biological plausibility based 
on previous research or that were significant 
based on a cut-off of p≤0.05 were retained in 
the final model.
Ethical considerations
Since data collection was a part of routine 
TB control efforts, individual patient 
consent or parental assent was not required. 
All data were safeguarded to protect patient 
confidentiality and no individual patient 
identifiers were retained in the study 
database. Participation of the US Centers 
for Disease Control and Prevention (CDC) 
and the South African National Department 
of Health in this project did not meet the 
definition of engagement in research on 
human subjects because the investigators 
did not interact with study subjects or 
have access to patient identifiable data, so 
separate institutional review board approval 
was not required. A formal written waiver 
for the need for ethics approval was issued 
by the CDC/DTBE associate director of 
science.
Results
Of 1 339 patients in the parent project, 598 
(44.7%) were excluded owing to missing 
information on final treatment outcome 
(n=130), DOT coverage (n=213) or both 
Records collected in the database
1 339 (100%)
Records with treatment outcome available
957 (71.5%)
Records with treatment outcome and DOT available
744 (55.6%)
Records with treatment outcome, DOT and treatment regimen
741 (55.3%)
382 (28.5%) excluded – missing
treatment outcome
213 (15.9%) excluded – missing DOT
3 (0.2%) excluded – missing
treatment regimen
Fig. 1. Selection of patient population (DOT = directly observed therapy).
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Table 1. Sociodemographic and clinical characteristics of the patient population
Characteristics
All collected cases
(N=1 339)
n (%)
Analytic cohort
(N=741)
n (%)
Excluded cases
(N=598)
n (%) p-value*
Gender 0.98
Male 720 (53.8) 399 (53.9) 321 (53.8)
Female 617 (46.2) 341 (46.1) 276 (46.2)
Age (years) 0.15
<8 120 (9.0) 74 (10.0) 46 (7.7)
≥8 1 216 (91.0) 667 (90.0) 549 (92.3)
Mean 34 33 35 0.03
Population type <0.0001
Urban 480 (35.9) 332 (44.8) 148 (24.8)
Rural 859 (64.1) 409 (55.2) 450 (75.3)
HIV status 0.02
Positive 735 (75.0) 444 (72.6) 291 (79.1)
Negative 245 (25.0) 168 (27.4) 77 (20.9)
Site of disease 0.1
Pulmonary 1 048 (81.4) 608 (82.8) 440 (79.4)
Extrapulmonary 240 (18.6) 126 (17.2) 114 (20.6)
Patient category 0.03
New patient 1 071 (85.5) 635 (87.7) 436 (82.6)
Retreat after default 37 (2.9) 16 (2.2) 20 (3.8)
Other previously treated 145 (11.6) 73 (10.1) 72 (13.6)
Relapse 99 (7.9) 55 (7.6) 44 (8.3)
Retreat after failure 18 (1.4) 6 (0.8) 12 (2.3)
Other 28 (2.3) 12 (1.7) 16 (3.0)
DOT N/A
Full DOT 465 (53.2) 443 (59.8) 22 (16.5)
Partial DOT 384 (43.9) 274 (37.0) 110 (82.7)
Intensive phase only 364 (41.6) 256 (34.6) 108 (81.2)
Continuation phase only 20 (2.3) 18 (2.4) 2 (1.5)
No DOT 25 (2.9) 24 (3.2) 1 (0.8)
Treatment regimen N/A
1: 2RHEZ/4RH 1 006 (75.7) 571 (77.0) 435 (72.7)
2: 2RHZES/1RHEZ/5RHE 195 (14.7) 88 (11.9) 107 (17.9)
3: 2RHZ/4RH 125 (9.4) 79 (10.7) 46 (7.7)
4: INH chemoprophylaxis 2 (0.1) 2 (0.3) 0 (0)
5: Other chemoprophylaxis 1 (0.1) 1 (0.1) 0 (0)
Inappropriate treatment N/A
Yes 53 (4.0) 35 (4.7) 18 (3.0)
No 1 207 (90.6)  697 (94.1) 516 (86.3)
Unknown 79 (5.4)  9(1.2) 64 (10.7)
Treatment outcome N/A
Favourable 771 (59.4) 617 (83.3) 154 (27.7)
Cured 388 (29.9) 329 (44.4) 59 (10.6)
Treatment completed 383 (29.5) 288 (38.9) 95 (17.1)
Continued...
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(n=252), or treatment regimen (n=3) (Fig. 1). Compared with the 
patients with complete data (analytic cohort, n=741), patients with 
a missing outcome had a different distribution of DOT categories: 
a lower proportion of full DOT but a higher proportion of partial 
DOT (Table 1). Additionally, the 213 patients with missing DOT 
data had worse outcomes than the 741 patients in the analytic cohort. 
The analytic cohort included cases who were younger on average 
than excluded cases (mean age 33 v. 35  years among excluded cases; 
p=0.03) and were less likely to be HIV-infected (72.6% v. 79.1%, 
p=0.02) and to live in rural settings (55.2% v. 75.3%; p<0.0001) 
(Table 1). There was no significant difference in gender distribution 
(approximately half were male: 53.9%; p=0.9) or site of disease (82.8% 
pulmonary v. 79.4% pulmonary disease; p=0.1).
Most patients in the analytic cohort (635, 87.7%) were new 
cases, although 89 (12.3%) were previously treated, including 55 
(7.6%) relapses and 22 (3.0%) retreated after failure or default. 
Seventeen patients had missing information on previous treatment. 
Approximately three-quarters of patients (571, 77.0%) received 
treatment regimen 1, 88 (11.9%) received regimen 2, and 79 (10.7%) 
received regimen 3. Thirty-five patients (4.8%), including 8 children 
(22.9%), were considered to have received an inappropriate regimen 
for TB treatment according to national guidelines. We were not able 
to assess appropriateness of treatment among 9 adult patients owing 
to missing information on patient category. Almost all patients 
(96.8%) received DOT during treatment: 443 (59.8%) received DOT 
during the entire treatment course, and 274 (37.0%) received DOT 
during either the intensive or continuation phase, including 256 
(34.6%) receiving DOT during the intensive phase only (Table 1).
Of the 635 new cases, 24 (3.8%) received inappropriate treatment 
regimens; 384 (60.5%) received DOT during the entire course of TB 
treatment, 230 (36.2%) received partial DOT during the intensive 
or continuation phase, and 21 (3.3%) did not receive DOT during 
treatment (Table 2). Among 89 retreated patients, 8 (9.0%) received 
inappropriate treatment regimens; 51 (57.3%) received DOT during 
the entire course of TB treatment, 36 (40.5%) received partial DOT, 
and 2 (2.3%) did not receive DOT during treatment (Table 2).
Among the 741 patients, 124 (16.7%) had a poor treatment 
outcome, including 66 (8.9%) who defaulted, 6 (0.8%) in whom 
Table 1 (continued). Sociodemographic and clinical characteristics of the patient population 
Characteristics
All collected cases
(N=1 339)
n (%)
Analytic cohort
(N=741)
n (%)
Excluded cases
(N=598)
n (%) p-value*
Poor 186 (14.4) 124 (16.7) 62 (11.2)
Treatment defaulted 111 (8.6) 66 (8.9) 45 (8.1)
Treatment failure 8 (0.6) 6 (0.8) 2 (0.4)
Died 67 (5.2) 52 (7.0) 15 (2.7)
Transferred out 111 (8.6) 0 (0) 111 (20.0)
Moved out 228 (17.6) 0 (0) 228 (41.1)
DOT = directly observed therapy; R = rifampicin; H = isoniazid; E = ethambutol; Z = pyrazinamide; S = streptomycin; 2RHEZ /4RH = the intensive phase is 2RHEZ, 2 months in total, treatment 
with rifampicin, isoniazid, ethambutol and pyrazinamide in fixed-dose combinations given 7 days a week; the continuation phase is 4RH, 4 months, treatment with rifampicin and isoniazid in 
fixed-dose combinations given 7 days a week; 2RHZES /1RHEZ /5RHE = the intensive phase is 2RHZES/1RHEZ, 3 months in total – for the first 2 months rifampicin, isoniazid, ethambutol and 
pyrazinamide in fixed-dose combinations and streptomycin injections given 7 days a week, in the 3rd month only rifampicin, isoniazid, ethambutol and pyrazinamide in fixed-dose combinations 
given 7 days a week; the continuation phase is 5RHE, 5 months, treatment with rifampicin, isoniazid and ethambutol in fixed-dose combinations given 7 days a week; 2RHZ /4RH = the intensive 
phase is 2RHZ, treatment with rifampicin, isoniazid and pyrazinamide in fixed-dose combinations given 7 days a week for 2 months; the continuation phase is 4RH, 4 months, treatment with 
rifampicin and isoniazid in fixed-dose combinations given 7 days a week; wINH chemoprophylaxis = prophylactic treatment with isoniazid; N/A = not applicable.
*Comparison of analytic cohort and excluded cases.
Table 2. Distribution of TB management practices and treatment outcomes by patient and population type (N=741)*
Characteristics
New patients (N=635)
n (%)
Retreated patients (N=89)
n (%)
Rural (N=332)
n (%)
Urban (N=409) 
n (%)
Inappropriate treatment 
Yes 24 (3.8) 8 (9.0) 17 (5.2) 18 (4.5)
No 611 (96.2) 81 (91.0) 311 (94.8) 386 (95.5)
DOT 
Full DOT 384 (60.5) 51 (57.3) 205 (61.7) 238 (58.2)
Partial DOT 230 (36.2) 36 (40.5) 125 (37.7) 149 (36.4)
No DOT 21 (3.3) 2 (2.3) 2 (0.6) 22 (5.4)
Treatment outcome
Cured 283 (44.6) 40 (44.9) 139 (41.9) 190 (46.4)
Treatment completed 250 (39.4) 28 (31.5) 129 (38.9) 159 (38.9)
Treatment defaulted 52 (8.2) 13 (14.6) 45 (13.6) 21 (5.1)
Treatment failure 4 (0.6) 2 (2.3) 2 (0.6) 4 (1.0)
Died 46 (7.2) 6 (6.7) 17 (5.1) 35 (8.6)
DOT = directly observed therapy.
*Missing information: of 741 patients, 17 had missing information on previous treatment and 9 had missing information on appropriateness of treatment.
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treatment failed, and 52 (7.0%) who died. Paradoxically, the 
proportion of patients with a poor outcome was lower among patients 
who received inappropriate treatment (5/35, 14.3%) compared with 
those on appropriate treatment (118/697, 17.0%). Patients receiving 
partial DOT during treatment and those who did not receive DOT 
had higher proportions of poor outcomes (78/256, 28.3% and 3/7, 
12.5%, respectively) than patients who received DOT during the 
entire course of the treatment (43/444, 9.7%) (Table 3).
In univariate analysis, predictors of poor treatment outcome 
were receiving partial DOT (RR 2.9, 95% CI 2.1 - 4.1; p<0.001) and 
having defaulted during a previous TB treatment episode (RR 3.1, 
95% CI 1.9 - 5.2; p=0.001) (Table 3). Patients who received DOT 
during the intensive phase had an increased risk of a poor outcome 
compared with patients who received DOT during the entire course 
of treatment (RR 3.1, 95% CI 2.2 - 4.3; p<0.001). There was no 
significant association between inappropriate regimen and treatment 
outcome. Stratified analysis did not reveal any effect modification 
of these associations by sociodemographic, clinical or treatment 
practice indicators.
In a multivariate regression model, having received DOT during only 
the intensive phase of treatment (adjusted risk ratio (aRR) 3.1, 95% 
CI 2.2 - 4.3) and a history of previous TB treatment default (aRR 
2.3, 95% CI 1.1 - 4.8) were independently associated with a poor 
outcome after adjusting for age, gender, HIV status and population 
type (Table 4).
Discussion
This evaluation provides a detailed description of TB treatment 
management practices in three provinces of SA, including assignment 
of treatment regimen and DOT coverage, and their impact on 
treatment outcomes. Our findings demonstrate that incomplete 
DOT, specifically receiving DOT during the intensive phase only, is 
independently associated with poor treatment outcome. Our results 
are consistent with previous research and programme evaluation 
findings on TB management practices citing standardised DOT 
coverage as essential to TB control.[3-6] A study evaluating DOT 
in KwaZulu-Natal demonstrated that the facilities with high DOT 
coverage had significantly better cure rates than those with low DOT 
Table 3. Association between sociodemographic, clinical and treatment factors and poor treatment outcome (N=741)* 
Characteristics
Poor outcome (N=124)
n (%)
Favourable outcome  (N=617)
n (%) RR 95% CI p-value
Gender 
Male 75 (18.8) 324 (81.2) 1.3 0.96 - 1.86 0.09
Female 48 (14.1) 293 (85.9) Reference    
Age (years)
<8 9 (12.2) 65 (87.8) 0.7 0.37 - 1.33 0.2
≥8 115 (17.2) 552 (82.8) Reference
Population type 
Rural 64 (19.3) 268 (80.7) 1.3 0.95 - 1.81 0.09
Urban 60 (14.7) 349 (85.3) Reference
HIV status 
Positive 82 (18.5) 362 (81.5) 1.6 0.98 - 2.44 0.06
Negative 20 (11.9) 148 (88.1) Reference
Site of disease 
Pulmonary 102 (16.8) 506 (83.2) Reference
Extrapulmonary 22 (17.5) 104 (82.5) 0.91 0.90 - 1.10 0.9
Patient category 
New patient 102 (16.1) 533 (83.9) Reference
Retreat after default 8 (50.0) 8 (50.0) 3.1 1.85 - 5.24 <0.0001
Other previously treated 13 (17.8) 60 (82.2) 1.1 0.66 - 1.87 0.7
Inappropriate treatment 
Yes 5 (14.3) 30 (85.7) 0.9 0.37 - 1.93 0.7
No 118 (16.9) 579 (82.1) Reference
DOT 
Full DOT 43 (9.7) 401 (90.3) Reference
Partial DOT 78 (28.3) 198 (71.7) 2.9 2.06 - 4.10 <0.0001
Intensive phase only 76 (29.5) 182 (70.5) 3.1 2.16 - 4.28 <0.0001
Continuation phase only 2 (11.1) 16 (88.9) 1.2 0.30 - 4.37 0.8
No DOT 3 (12.5) 4 (87.5) 1.3 0.43 - 3.86 0.7
RR = risk ratio; CI = confidence interval; DOT = directly observed therapy.
*Missing information: of 741 patients, 17 had missing information on previous treatment and 9 had missing information on appropriateness of treatment.
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coverage (p=0.045).[6] A Nigerian study reported that implementing 
DOT in hospitals led to a significant increase in the number 
of patients completing treatment and a significant reduction in 
mortality among TB patients.[4]
DOT helps to ensure that patients adhere to and complete TB 
treatment regimens. A study in Zambia established that 29.8% of 
TB patients stopped taking their TB treatment once they started 
feeling better.[15] Similarly, researchers in Uganda reported that the 
continuation phase of TB treatment was significantly associated with 
non-adherence to TB treatment (odds ratio 6.2; p<0.001).[16] These 
previous studies support our finding that patients who do not receive 
DOT during the continuation phase have a threefold increased risk 
for poor treatment outcome compared with patients who receive 
DOT throughout the course of treatment.
The majority of patients received appropriate treatment regimens, 
with 96.2% of new and 91.0% of retreatment patients receiving 
the recommended therapy according to the NTP guidelines. 
Inappropriate treatment regimens were not, however, associated 
with poor treatment outcomes. This may be because the regimens 
classified as inappropriate include some that were ‘stronger’ or 
‘longer’ than the standard recommended regimens. We did identify 
that patients with a history of treatment default are at an increased 
risk of poor outcome compared with new patients. The increased risk 
of poor outcome associated with partial DOT and previous default 
illustrates the importance of adherence to TB treatment in achieving 
a successful outcome.
This study has several limitations. Owing to missing information 
on TB treatment regimen, DOT coverage and treatment outcome, 
598 cases (44.7%) were excluded from analysis. Although the 
gender distribution was similar between analysed and excluded 
cases, parameters such as age, population type, HIV status, patient 
category, DOT use and treatment outcomes were different. However, 
the purpose of this analysis was to evaluate the status of the existing 
TB control programme in these locations, not to make inferences 
regarding the larger population of all TB patients. Representative 
sampling is therefore less of an issue, and the results reported reflect 
the actual situation in this sample. Further, the data were obtained 
retrospectively from medical and surveillance documents recorded 
as part of programmatic surveillance, not as part of a research 
study. It is therefore possible that the recording of information 
may not have been standardised across different health facilities 
and providers. Also, owing to the presence of multiple sources of 
information, decision rules were established to resolve discrepant 
values. Unfortunately, there was no mechanism to determine which 
data source most accurately reflects patient information. While most 
studies rely on a single source document that may not accurately 
reflect the true value, this analysis was able to maximise the 
completeness and reliability of information by utilising several data 
sources. Because we were not able to assess inappropriate treatment 
in more detail from a clinical perspective owing to lack of patient 
information on severity of disease and smear status of paediatric 
patients, this evaluation may have overestimated the actual number 
of patients receiving inappropriate treatment. However, we believe 
this information would have impacted on our results only minimally 
because few clinical indications would have led to reclassification of 
regimen appropriateness, as regimen standards are based on general 
patient groups (new/retreatment; adult/child). Finally, there is a 
possibility of confounding by other factors that were not available 
in the current dataset. However, we examined all available socio-
demographic, clinical and treatment factors as potential confounders 
and effect modifiers in the current analyses.
In conclusion, our evaluation demonstrated a high level of adherence 
to NTP treatment and management guidelines in the selected provinces 
of SA. Receiving DOT during only the intensive phase of treatment 
and a history of previous TB treatment default were independently 
associated with poor treatment outcome. The results suggest that 
health facilities in these provinces may need additional training and 
resources to ensure that all patients receive DOT throughout the course 
of treatment. These results underscore the importance of DOT as a 
critical element in overall TB programme success.
Disclaimer. The findings and conclusions in this report are those of the 
authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention, the University of South Florida and 
the South African National Department of Health.
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*Multivariate binomial regression adjusted for age, gender, HIV status and population type.
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